Clinical Validation of Lophius Biosciences Kit T-Track® CMV in Kidney Transplant Recipients

Inclusion Criteria: * Patient receiving a kidney graft * Recipient being CMV-seropositive prior transplantation and receiving a graft from either a CMV-seropositive or from a seronegative donor (intermediate risk groups, D+/R+; D-/R+,) * Patient scheduled to follow the preemptive antiviral strategy with oral valganciclovir or intravenous ganciclovir after transplantation * Patient receiving the standard triple immunosuppressive regimen (CNI, MMF/MPA or mTOR inhibitors, steroids), with or without induction therapy (except ATG) as start therapy after transplantation * Male or female patient at least 18 years of age * Written informed consent Exclusion Criteria: * Patient is scheduled for the optional visit 1, but requires ongoing treatment with a systemic immunosuppressive drug already prior to kidney transplantation (except induction therapy other than ATG) * Patient receiving ATG as induction therapy * Patient is known to be positive for HIV or suffering from chronic hepatitis infections * Patient has significant uncontrolled concomitant infections or other unstable medical conditions before transplantation that could interfere with the study objectives * Patient is unable to comply with the visit schedule in the protocol * Patient has any form of substance abuse, psychiatric disorder or condition that, in the opinion of the investigator may invalidate communication with the investigator